Oscar Health came into this print with a mixed recent run, down over 10% in the past week and month but still sharply higher over the last quarter. The stock jumped about 5% today, and that move lines up with what the income statement just showed. Q2 delivered about US$4.9b in revenue and roughly US$362m in net income, reflecting the company’s shift to profitability.

The real swing factor was profitability quality. Medical Loss Ratio and selling, general and administrative costs both moved in Oscar Health’s favor, turning what had been a story about survival into one centered on earnings power.

Love that Oscar Health has tipped into profitability but wondering which insurers pair earnings power with stronger balance sheets and scale? Take a look at the list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$4,880.22m vs. US$2,863.95m (very large increase)
• Net Income, Q2 2026 vs. Q2 2025: US$361.81m vs. a loss of US$228.36m (move from loss to profit)
• Basic EPS, Q2 2026 vs. Q2 2025: US$1.20 vs. a loss of US$0.89 per share (move from loss to profit)
• Medical Loss Ratio (MLR, Q2 2026 vs. Q2 2025): 79.2% vs. roughly 91% (material improvement in underwriting margin)

Prefer clear charts instead of another wall of earnings tables and footnotes? See Oscar Health’s full visual financial picture, with a focus on its latest profitability and earnings trend, in the company report for Oscar Health.

Evaluating Oscar Health’s Margin-Led Bull Story

The bullish view on Oscar Health hinges on tech-driven efficiency, cleaner medical costs and membership gains turning the ACA-focused model into a durable earnings engine. Q2 hits several of those milestones. Effectuated membership reached 2.96m, up 46% year on year, which backs the idea that scale is building. The Medical Loss Ratio improved to 79.2%, roughly 12 points better than a year ago, supported by disciplined pricing and favorable risk adjustment, which is exactly where bulls expected proof that underwriting can hold.

Administrative efficiency is also moving the way optimists wanted. SG&A dropped to 14.2% of revenue, a record low, with management linking that to AI and platform-driven process gains. The raised full-year earnings from operations outlook to US$500m to US$700m, while keeping revenue guidance unchanged, reinforces that the current leg of the story is primarily about margins, not just growth.

Reveal where the surface looks calm, yet the multi year models for Oscar Health start to diverge, and where the street quietly sees the next earnings inflection. Access the full set of analyst estimates for Oscar Health.

Oscar Health Bears Still Focused On Sustainability Gaps

The harshest critics of Oscar Health argue that ACA concentration and fragile medical trends make current margins temporary. This quarter weakens some of that claim but does not fully clear it. A Q2 Medical Loss Ratio of 79.2% and strong earnings from operations directly counter the idea of structurally high medical losses. However, management also acknowledged that part of the benefit came from favorable prior-period risk adjustment and that early 2026 morbidity data covers only four months. That leaves the door open for bears who worry about reversion.

Concerns around policy and enrollment risk also stay alive. Guidance now assumes faster membership churn in the second half as CMS tightens eligibility checks. Revenue guidance is unchanged, which helps the story, yet it means the clean, low churn some investors wanted to see as a milestone has not arrived.

After a sharp swing into profitability, are Oscar Health’s cleaner medical trends and insider moves just the tip of the iceberg, or part of a deeper pattern? Review the full risk analysis for Oscar Health which shows 2 important warning signs.

Take Control Of Your Next Move

If Oscar Health’s sharp shift into profitability and improving Medical Loss Ratio caught your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a setup that fits your plan. Once you own it or any other stock, use the Portfolio Command Center to cut through noise and focus on the key updates that actually matter for your holdings. For the longer journey, tap into the collective experience of other investors through the Community and see how different perspectives line up with your thesis. By spotting hidden catalysts and risks early, you give yourself a better chance to stay ahead of the market and act with confidence.

Seeking Alternatives Beyond Oscar Health?

Fresh ideas can move fast, and the best breakout setups often get caught quietly before momentum takes off. Scan these under the radar options while it matters and act now.

• Spot established income engines that still offer resilience by reviewing a curated 8 dividend fortresses before yields or valuations shift away from your comfort zone.
• Track future facing infrastructure plays that could gain momentum from AI adoption by scanning the focused group of 55 AI infrastructure stocks while they remain under the radar for now.
• Find potential compounding machines with disciplined management by checking the hand picked lineup of 20 top founder-led companies before the crowd fully catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.